Olema Pharmaceuticals Net Debt Over Time
| OLMA Stock | USD 10.12 0.40 4.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Olema Pharmaceuticals Performance and Olema Pharmaceuticals Correlation. Olema |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Debt Analysis
Compare Olema Pharmaceuticals and related stocks such as Sana Biotechnology, Cullinan Oncology LLC, and ATyr Pharma Net Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SANA | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (31.8 M) | (340.1 M) | (142.1 M) | (68.5 M) | (29.4 M) | (30.9 M) |
| CGEM | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (63.2 M) | (168.2 M) | (430.9 M) | (544.9 M) | (94.8 M) | (99.6 M) |
| ZNTL | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (81.6 M) | (53 M) | (13.8 M) | 2.1 M | 15.1 M | 15.9 M |
| MOLN | (96.1 M) | (96.1 M) | (96.1 M) | (96.1 M) | (188.4 M) | (195.4 M) | (149.7 M) | (131.3 M) | (99 M) | (73.2 M) | (126.5 M) | (65.8 M) | (83.1 M) | (63.7 M) | (66.8 M) |
| MLYS | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | (10.6 M) | (87.7 M) | (49.3 M) | (51.8 M) |
| ANTX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.1 M) | (12.1 M) | (27.2 M) | (15.6 M) | (16.4 M) |
| PHVS | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (5.4 M) | (20.3 M) | (98.6 M) | (209.1 M) | (161.4 M) | (391 M) | (371.4 M) |
| PEPG | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (9.8 M) | (132.9 M) | (157.2 M) | (60.7 M) | (63.7 M) |
| GLUE | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | 26.1 M | (346.1 M) | (7.9 M) | (82.1 M) | (86.2 M) |
| DSGN | 618 K | 618 K | 618 K | 618 K | 618 K | 618 K | 618 K | 618 K | 618 K | 618 K | (2.4 M) | (294.9 M) | (22.8 M) | (18.1 M) | (19.1 M) |
| ERAS | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (62.4 M) | (341.7 M) | (229.1 M) | (37.2 M) | (39.1 M) |
| IRON | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | (86.4 M) | (193.3 M) | (358.3 M) | (340.4 M) |
| LRMR | (50.5 M) | (50.5 M) | (50.5 M) | (50.5 M) | (50.5 M) | (29.2 M) | (28.8 M) | (20.8 M) | (28.7 M) | (912 K) | (61.6 M) | (64.1 M) | (21.4 M) | (21.2 M) | (22.3 M) |
| FENC | (52.1 K) | (5.3 M) | (2.3 M) | (1.7 M) | (2.3 M) | (942 K) | (3.9 M) | (28.3 M) | (22.8 M) | (13.7 M) | (30.3 M) | (16.1 M) | 1.1 M | 17.7 M | 18.6 M |
| OBIO | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (4.3 M) | (7.9 M) | (28.9 M) | (27.4 M) |
| NVCT | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (20 M) | (19.1 M) | (20.1 M) |
| CNTA | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (519.4 M) | (323.8 M) | (43.4 M) | (45.6 M) |
Olema Pharmaceuticals and related stocks such as Sana Biotechnology, Cullinan Oncology LLC, and ATyr Pharma Net Debt description
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.My Equities
My Current Equities and Potential Positions
| Olema Pharmaceuticals | OLMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 10.12
Check out Olema Pharmaceuticals Performance and Olema Pharmaceuticals Correlation. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Olema Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.